SignaLife
Non-invasive Continuous Blood Gas and pH Sensor
Company Overview
Snapshot
Founded in March 2021 by Roy Nissim, SignaLife operates with 1–10 employees. The company has raised $2.7 million across three funding rounds and in April 2025 initiated its second clinical trial at Sheba Medical Center's NICU.
Business overview
SignaLife is a technology company specializing in AI optic sensors for medical and well-being applications within the Health Tech & Life Sciences sector. The company develops products designed to provide non-invasive and continuous pH and blood gas measurements for patients in ICU and NICU settings. Its solutions aim to reduce infection risks, minimize blood draws, and support improved treatment decisions in healthcare.
Strategic signal
SignaLife's initiation of a second clinical trial in April 2025 at Sheba Medical Center's NICU, following promising initial results from its first human trial, signals significant progress in validating its non-invasive continuous monitoring technology. This advancement demonstrates the company's commitment to clinical development and could accelerate its path to market, offering a strong indicator of future growth potential to investors.
Log in to access full profile ›Company Intelligence Q&A
- What is SignaLife's core technology?
- SignaLife develops lifesaving AI optic sensors designed for non-invasive and continuous monitoring of pH and blood gases in medical and well-being applications.
- When was SignaLife founded?
- SignaLife was founded in March 2021.
- Who is a co-founder of SignaLife?
- Roy Nissim is a co-founder and CSO of SignaLife.
- What was a key clinical development for SignaLife in early 2025?
- In April 2025, SignaLife recruited the first baby for its second clinical trial at Sheba Medical Center’s NICU, with promising pH results.
- What is the total capital raised by SignaLife?
- SignaLife has raised $2.7 million across three funding rounds.